Cerus Corporation to Participate in the Goldman Sachs 46 th Annual Global Healthcare Conference 2025
A live webcast of the presentation can be accessed via the Events & Presentation section of Cerus' Investor Relations website at ir.cerus.com. A replay of the webcast will be available on Cerus Investor Relations website shortly after the event for 30 days.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
The Hanover Insurance Group, Inc. Announces Pricing of $500 Million Senior Notes Offering
WORCESTER, Mass., Aug. 19, 2025 /PRNewswire/ -- The Hanover Insurance Group, Inc. (NYSE: THG) today announced it has priced a registered offering of $500 million aggregate principal amount of senior, unsecured 5.50% notes due September 1, 2035 (the "Notes"). The company plans to use the net proceeds from the issuance of the Notes to repay its outstanding 7.625% Senior Notes due October 2025, repay or redeem its outstanding 4.500% Senior Notes due April 2026 (collectively, the "Debentures") and for general corporate purposes. The company anticipates the debt offering will close on or around August 21, 2025, subject to customary closing conditions. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC are acting as the joint book-running managers for the offering. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction. The offering is being made pursuant to an effective shelf registration filed with the Securities and Exchange Commission ("SEC") on August 18, 2025. A prospectus and prospectus supplement related to this offering have been filed with the SEC. This press release does not constitute a notice of redemption with respect to, or any offer to purchase, the Debentures. Any such notice will be given to holders of the Debentures in a manner prescribed in the indenture governing the Debentures. Copies of the prospectus and related prospectus supplement may be obtained at no cost by visiting the SEC website at Alternatively, copies or information concerning this offering may be obtained by contacting the joint book-running managers: Goldman Sachs & Co. LLC at +1 (800) 828-3182, J.P. Morgan Securities LLC at +1 (212) 834-4533, or Morgan Stanley & Co. LLC at +1 (866) 718-1649. About The Hanover The Hanover Insurance Group, Inc. is the holding company for several property and casualty insurance companies, which together constitute one of the largest insurance businesses in the United States. The company provides exceptional insurance solutions through a select group of independent agents and brokers. Together with its agent partners, The Hanover offers standard and specialized insurance protection for small and mid-sized businesses, as well as for homes, automobiles, and other personal items. Forward-Looking Statements This news release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Those forward-looking statements are subject to various risks and uncertainties and include all statements that are not historical statements of fact and those regarding our intent, belief or expectations with respect to future events and financial performance and the debt offering, including the expected closing of the debt offering and the use of proceeds from the debt offering. The company cautions investors that any such forward-looking statements are not guarantees of future performance, and actual results could differ materially. Investors are directed to consider the risks and uncertainties in the company's business that may affect future performance and that are discussed in readily available documents, including those risks which are discussed in the company's annual report and other documents filed by the company with the SEC. Contacts: Investors: Media:Oksana Lukasheva Emily P. Trevallion(508) 525-6081 (508) 855-3263Email: olukasheva@ Email: etrevallion@ View original content to download multimedia: SOURCE The Hanover Insurance Group, Inc.
Yahoo
9 minutes ago
- Yahoo
Why is GDRX stock up 30% today? GoodRx strikes deal to sell Ozempic and Wegovy after Novo Nordisk's breakup with Hims
Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the lowest-ever out-of-pocket prices for Ozempic and Wegovy. Unsold completed new-build inventory is so high this $34B homebuilder is turning to investors 'Job hugging' is the newest career trend: Here's what it means—and why Gen Z is into it Spotify just redesigned the way you'll 'listen' to audiobooks According to a press release posted early on August 18, GoodRx has struck a deal with the pharmaceutical giant Novo Nordisk to sell its popular semaglutide medications, Ozempic and Wegovy, for just $499 per month to 'eligible self-paying customers.' GoodRx doesn't sell or dispense any drugs itself, but rather provides savings and coupons that can be applied in pharmacies. Its exclusive Ozempic and Wegovy offerings, available starting today, are the lowest out-of-pocket costs for the medications available on the market. The news comes just weeks after Novo Nordisk cut ties with the telehealth company Hims & Hers Health (NYSE: HIMS) over claims that Hims & Hers was selling 'knockoff' versions of Wegovy. It's a dispute that reflects a broader discussion around whether compounded semaglutide drugs—or non-FDA approved versions of brand-name medicines—are a violation of intellectual property laws. As of this writing, GoodRx's stock is up by more than 30% since market close. Here's what to know about Novo Nordisk's latest partnership and its ongoing legal battles against compounded GLP-1s. GoodRx's collaboration with Novo Nordisk In the last year alone, GoodRx reports that nearly 17 million people visited the site searching for information and savings on GLP-1 medications—a 22% increase from the previous year. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' Wendy Barnes, GoodRX president and CEO, said in the press release. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them.' In the past, a spokesperson told Fast Company, GoodRx has worked with both Novo Nordisk and its competitor Eli Lilly to offer commercially insured patients manufacturer savings cards on GLP-1s. The company has also offered savings on other types of weight loss/diabetes treatments, including Contrave, Dexcom G7, Lantus, and Qsymia. However, this is the first time that GoodRx has offered a cash price for a GLP-1. The $499 monthly self-pay cost will be available at more than 70,000 retail locations nationwide. Novo Nordisk's current legal battles over compounded GLP-1s So far, investors' response to GoodRx's new collaboration has been overwhelmingly positive. It stands in sharp contrast to Hims & Hers' recent breakup with Novo Nordisk, which caused the telehealth company's share prices to plummet in late June. Hims & Hers and Novo Nordisk parted ways over Hims & Hers' offering of compounded versions of Wegovy. Back in 2022, the Food and Drug Administration (FDA) declared a shortage of GLP-1 medications including Ozempic and Wegovy. Under this shortage notice, pharmacies were permitted to make compounded versions of the brand-name drugs using their active ingredient, semaglutide, and sell them at a lower cost. However, Hims & Hers has continued to sell its compounded version of Wegovy long after the FDA lifted the shortage back in February. Now, Novo Nordisk is arguing that these compounded drugs are both a violation of its intellectual property and potentially dangerous to patients, due to their lack of FDA approval. Early this month, Novo Nordisk announced 14 new lawsuits against small pharmacies, telehealth providers, and weight-loss clinics over compounded versions of Ozempic and Wegovy—bringing its total cases filed on the matter up to more than 130 in 40 states. Experts say that federal compounding laws are just vague enough to allow for various interpretations, meaning that Novo Nordisk's current legal challenges could shape the way courts interpret those boundaries in the future. In a statement to Yahoo Finance, Barnes offered a clear look into GoodRx's stance on compounded drugs: 'There's no question we could have tried to do something sooner from a compounded alternative pathway, but we have been very clear in our belief that it needed to be FDA-approved, lawfully approved. It just wasn't a pathway that we were going to support,' she said. This post originally appeared at to get the Fast Company newsletter:
Yahoo
an hour ago
- Yahoo
Dick's Sporting Goods (DKS) Increases Despite Market Slip: Here's What You Need to Know
Dick's Sporting Goods (DKS) closed the most recent trading day at $227.57, moving +1.87% from the previous trading session. This change outpaced the S&P 500's 0.59% loss on the day. Meanwhile, the Dow gained 0.02%, and the Nasdaq, a tech-heavy index, lost 1.46%. Coming into today, shares of the sporting goods retailer had gained 3.69% in the past month. In that same time, the Retail-Wholesale sector gained 3.3%, while the S&P 500 gained 2.49%. The investment community will be closely monitoring the performance of Dick's Sporting Goods in its forthcoming earnings report. The company is scheduled to release its earnings on August 28, 2025. On that day, Dick's Sporting Goods is projected to report earnings of $4.29 per share, which would represent a year-over-year decline of 1.83%. Meanwhile, the latest consensus estimate predicts the revenue to be $3.6 billion, indicating a 3.57% increase compared to the same quarter of the previous year. For the full year, the Zacks Consensus Estimates project earnings of $14.38 per share and a revenue of $13.9 billion, demonstrating changes of +2.35% and +3.37%, respectively, from the preceding year. Any recent changes to analyst estimates for Dick's Sporting Goods should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.05% higher. Dick's Sporting Goods is currently sporting a Zacks Rank of #3 (Hold). Digging into valuation, Dick's Sporting Goods currently has a Forward P/E ratio of 15.53. This valuation marks no noticeable deviation compared to its industry average Forward P/E of 15.53. We can additionally observe that DKS currently boasts a PEG ratio of 3.19. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Retail - Miscellaneous was holding an average PEG ratio of 3.11 at yesterday's closing price. The Retail - Miscellaneous industry is part of the Retail-Wholesale sector. This industry, currently bearing a Zacks Industry Rank of 157, finds itself in the bottom 37% echelons of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DICK'S Sporting Goods, Inc. (DKS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
